PENGARUH TELMISARTAN TERHADAP RESISTENSI INSULIN PADA PASIEN HIPERTENSI DENGAN PENYAKIT GINJAL KRONIS YANG MENJALANI HEMODIALISIS REGULAR (PGK-HD) (Penelitian Dilaksanakan di Unit Hemodialysis RS Bhayangkara H.S. Samsoeri Mertojoso Surabaya)
Patients with end-stage renal disease (ESRD) are known to have insulin resistance, which is closely associated with atherosclerosis and other cardiovascular mortality. Telmisartan as one of the angiotensin receptor blocker mostly known for its antihypertension activity, has been reported to have...
Saved in:
| Main Author: | |
|---|---|
| Format: | Theses and Dissertations NonPeerReviewed |
| Language: | English English |
| Published: |
2017
|
| Subjects: | |
| Online Access: | http://repository.unair.ac.id/63880/1/abstrak.pdf http://repository.unair.ac.id/63880/2/TESIS-MAHADRI%20DHRIK-051315153025.pdf http://repository.unair.ac.id/63880/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Universitas Airlangga |
| Language: | English English |
| Summary: | Patients with end-stage renal disease (ESRD) are known to have insulin
resistance, which is closely associated with atherosclerosis and other cardiovascular mortality.
Telmisartan as one of the angiotensin receptor blocker mostly known for its antihypertension
activity, has been reported to have beneficial effect on reducing insulin resistance through its
activity as a partial agonist of PPAR-Ɣ. However, such effect has never been clarified in
hemodialysis patient. We evaluated the effect of Telmisartan on Insulin resistance in
hypertensive patient with ESRD and regular hemodialysis.
OBJECTIVES: To analyze the effect of Telmisartan on Insulin resistance in hypertensive
patients with end-stage renal disease and regular hemodialysis which is indicated by fasting
plasma glucose level, fasting plasma insulin level, and HOMA-IR.
METHODS: This observational prospective study was carried in hemodialysis unit of
Bhayangkara Hospital in Surabaya from June-November 2016. Patients who meet the inclusion
criteria were treated daily with 80 mg of per oral telmisartan for 12 weeks. Then the changes of
fasting blood glucose level, insulin plasma level, and HOMA-IR were evaluated.
RESULTS: There are 16 patients met inclusion criteria of the study (12 males and 4 females).
Telmisartan significantly reduced insulin plasma level (7,09 ± 4,11 to 5,03 ± 3,15 uU/dl,
P=0,001), and HOMA-IR (1,69 ± 1,28 to 1,11 ± 0,79, P=0,002). However, it did not significantly
affect fasting plasma glucose level (89.06 ± 20.06 to 84.56 ± 10.91 mg/dl, p=0,187).
CONCLUSION: In this study, we found that telmisartan can reduce the insulin resistance in
hypertensive patient with End-Stage Renal Disease and Regular Hemodialysis |
|---|